OPIANT PHARMACEUTICALS, INC.: 10-Q filed 2017-06-14
What OPIANT PHARMACEUTICALS, INC. reported in its quarterly report filed 2017-06-14 (fiscal Q3 2017): 28 published measures, 82 facts as tagged in accession 0001144204-17-032535.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-06-14
- Fiscal period
- fiscal Q3 2017
- Accession
- 0001144204-17-032535 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OPIANT PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | 9,801,093 | USD | |
| At 2016-07-31 | 1,881,878 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | 5,515,806 | USD | |
| At 2016-07-31 | 6,586,834 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | 4,285,287 | USD | |
| At 2016-07-31 | -4,704,956 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | 9,680,454 | USD | |
| At 2016-07-31 | 1,481,393 | USD | |
| At 2016-04-30 | 2,363,465 | USD | |
| At 2015-07-31 | 434,217 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | -3,129,608 | USD | 89 |
| 2016-08-01 to 2017-04-30 | 6,919,554 | USD | 273 |
| 2016-02-01 to 2016-04-30 | 416,128 | USD | 90 |
| 2015-08-01 to 2016-04-30 | -6,723,849 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2017-04-30 | 0 | USD | 273 |
| 2015-08-01 to 2016-04-30 | 6,528 | USD | 274 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | 18,116 | USD | 89 |
| 2016-08-01 to 2017-04-30 | 14,674,258 | USD | 273 |
| 2016-02-01 to 2016-04-30 | 2,605,097 | USD | 90 |
| 2015-08-01 to 2016-04-30 | 9,585,097 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | -54,265,788 | USD | |
| At 2016-07-31 | -61,185,342 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | 2,014,141 | shares | 89 |
| 2016-08-01 to 2017-04-30 | 2,004,143 | shares | 273 |
| 2016-02-01 to 2016-04-30 | 1,916,554 | shares | 90 |
| 2015-08-01 to 2016-04-30 | 1,882,088 | shares | 274 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | 2,014,141 | shares | 89 |
| 2016-08-01 to 2017-04-30 | 2,251,127 | shares | 273 |
| 2016-02-01 to 2016-04-30 | 2,734,760 | shares | 90 |
| 2015-08-01 to 2016-04-30 | 1,882,088 | shares | 274 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | -1.55 | USD/shares | 89 |
| 2016-08-01 to 2017-04-30 | 3.45 | USD/shares | 273 |
| 2016-02-01 to 2016-04-30 | 0.22 | USD/shares | 90 |
| 2015-08-01 to 2016-04-30 | -3.57 | USD/shares | 274 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | -1.55 | USD/shares | 89 |
| 2016-08-01 to 2017-04-30 | 3.07 | USD/shares | 273 |
| 2016-02-01 to 2016-04-30 | 0.15 | USD/shares | 90 |
| 2015-08-01 to 2016-04-30 | -3.57 | USD/shares | 274 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | 0 | USD | 89 |
| 2016-08-01 to 2017-04-30 | 0 | USD | 273 |
| 2016-02-01 to 2016-04-30 | 0 | USD | 90 |
| 2015-08-01 to 2016-04-30 | 0 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | 3,695 | USD | |
| At 2016-07-31 | 6,521 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | -3,165,470 | USD | 89 |
| 2016-08-01 to 2017-04-30 | 6,893,397 | USD | 273 |
| 2016-02-01 to 2016-04-30 | 411,862 | USD | 90 |
| 2015-08-01 to 2016-04-30 | -6,687,605 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | 9,779,365 | USD | |
| At 2016-07-31 | 1,856,295 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | 3,128,722 | USD | |
| At 2016-07-31 | 4,236,834 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | 0 | USD | |
| At 2016-07-31 | 312,498 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | 3,183,586 | USD | 89 |
| 2016-08-01 to 2017-04-30 | 7,780,861 | USD | 273 |
| 2016-02-01 to 2016-04-30 | 2,193,235 | USD | 90 |
| 2015-08-01 to 2016-04-30 | 16,272,702 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | 1,103,319 | USD | 89 |
| 2016-08-01 to 2017-04-30 | 1,889,989 | USD | 273 |
| 2016-02-01 to 2016-04-30 | 1,059,627 | USD | 90 |
| 2015-08-01 to 2016-04-30 | 2,814,520 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | 2,020,380 | shares | |
| At 2016-07-31 | 1,992,433 | shares |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | 3,842 | USD | |
| At 2016-07-31 | 1,016 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-04-30 | 18,033 | USD | |
| At 2016-07-31 | 19,062 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | 1,995,892 | USD | 89 |
| 2016-08-01 to 2017-04-30 | 4,567,898 | USD | 273 |
| 2016-02-01 to 2016-04-30 | 1,040,608 | USD | 90 |
| 2015-08-01 to 2016-04-30 | 13,155,931 | USD | 274 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2017-04-30 | 3,855 | USD | 273 |
| 2015-08-01 to 2016-04-30 | 1,187 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-02-01 to 2017-04-30 | 35,862 | USD | 89 |
| 2016-08-01 to 2017-04-30 | 26,157 | USD | 273 |
| 2016-02-01 to 2016-04-30 | 4,266 | USD | 90 |
| 2015-08-01 to 2016-04-30 | -36,244 | USD | 274 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2017-04-30 | -312,498 | USD | 273 |
| 2015-08-01 to 2016-04-30 | 0 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2017-04-30 | 1,250,196 | USD | 273 |
| 2015-08-01 to 2016-04-30 | -108,639 | USD | 274 |
Inspect the source
- Entity
- OPIANT PHARMACEUTICALS, INC. / CIK 0001385508
- Captured
- SEC response SHA-256
2364e629461ca2a795db263ee8044ac545282f6ca3e3ea28eb9ce90156d0a955
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001385508.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))